Trial Profile
A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Nov 2012
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Stallergenes SA
- 26 Nov 2012 New trial record